May 17, 2018
Title: Planning for a Successful Failure
Date/Time: June 7, 2018 from 10:30 am – 11:45 am
Location: Room 257AB, Level 2 at the Boston Convention and Exhibition Center
BIO 2018 will be taking place on June 4-7 in Boston, MA and Haug Partners LLP is proud to announce it will be hosting a panel discussion titled Planning for a Successful Failure. The session will be moderated by partner John Dougherty and includes panelists from leading companies in the pharmaceutical industry.
This panel will look at how collaboration, acquisition and license agreements are written with an optimistic view of the chances for commercial success. Nevertheless, they can neglect to clarify the parties’ expectations in the event of program failure, delay or disagreement—all common occurrences in biopharma development and commercialization.
This panel looks to the experience of deal-makers, alliance managers and sell-and buy-side dispute managers on how both to anticipate and to avoid costly disputes at three critical stages: 1) during deal formation and the exchange of terms; 2) during post-closing operations and integration; and 3) in formal disputes. The panelists’ advice and lessons will assist licensors/licensees, sellers/buyers and collaborators of single and multi-asset programs and platform technologies.
John Dougherty, Partner, Haug Partners LLP, Moderator
Christine Carberry, Chief Operating Officer, Keryx Biopharmaceuticals
Don Morrissey, Executive Director, SRS Acquiom
Jeffrey Prowda: SVP Associate General Counsel and Head Counsel Corporate, Shire
Jason Steinhart: Associate General Counsel, Litigation & Investigations, Sanofi US